Atom | Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Due Dates: November 28, 2025 (forecasted)

Funding Amounts: $40,000,000 total program funding; approximately 4 awards anticipated

Summary: Supports research utilizing data from expanded access to investigational drugs for ALS in intermediate-size patient populations not eligible for ongoing clinical trials.

Key Information: This is a forecasted opportunity; applications are not yet being accepted.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

Sign in to see full grant listing